- 1 Title: Menopausal symptom burden as a predictor of mid- to late-life cognitive function and
- 2 mild behavioral impairment symptoms: A CAN-PROTECT study.
- 3 Short Title: Menopausal Symptom Burden
- 4 Author Names: Jasper F.E. Crockford^{1,2¶}, Dylan X Guan^{1,3,4¶}, Gillian Einstein^{5,6}, Clive Ballard⁷,
- 5 Bryon Creese⁷, Anne Corbett⁷, Ellie Pickering⁷, Adam Bloomfield⁷, Pamela Roach^{1,8,9}, Eric E
- 6 Smith^{1,2,4,8} Zahinoor Ismail^{1-2,4,7-10*}
- 7 (1) University of Calgary, AB, Canada
- 8 (2) Department of Clinical Neurosciences, University of Calgary, AB, Canada
- 9 (3) Faculty of Graduate Studies, University of Calgary, AB, Canada
- 10 (4) Hotchkiss Brain Institute, University of Calgary, AB, Canada
- 11 (5) Department of Psychology, University of Toronto, ON, Canada
- 12 (6) Rotman Research Institute, Baycrest Hospital, Toronto, ON, Canada
- 13 (7) Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter,
- 14 Exeter, UK
- 15 (8) Department of Community Health Sciences, University of Calgary, AB, Canada
- 16 (9) O'Brien Institute for Public Health, University of Calgary, AB, Canada
- 17 (10) Department of Psychiatry, University of Calgary, AB, Canada
- 18 *Corresponding Author:
- 19 Email: <u>ismailz@ucalgary.ca (ZI)</u>
- 20 These authors contributed equally to this work.
- 21 & These authors also contributed equally to this work.
- 22

23

24 Abstract

25 Background: Recent evidence suggests the experience of menopausal symptoms (i.e.,

26 perimenopausal symptoms) may be associated with cognitive and behavioural changes. We

27 investigated these two relationships in a sample of post-menopausal females.

28 **Design:** Cross-sectional observational study.

29 Setting: Participant data was collected from the Canadian Platform for Research Online to

30 Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging

31 (CAN-PROTECT) study.

32 Participants: 896 post-menopausal female participants.

33 Methods: Menopausal symptom burden was operationalized by summing the total number of

34 recalled perimenopausal symptoms experienced. Cognitive function was measured using the

35 Everyday Cognition (ECog-II) Scale, with higher scores reflecting greater severity. Mild

36 Behavioral Impairment (MBI) was measured using the Mild Behavioral Impairment Checklist

37 (MBI-C), with higher scores reflecting greater severity. A negative-binomial regression model

38 examined the relationship between menopausal symptom burden and cognitive function, while a

39 zero-inflated negative binomial regression model examined the relationship between menopausal

40 symptom burden and MBI symptoms. Models adjusted for age, years of education, age of

41 menopausal onset, type of menopause, and hormone therapy (HT). Age of menopausal onset and

42 use of HT in the two associations were investigated with moderation analyses.

43 **Results:** Greater menopausal symptom burden was associated with higher ECog-II total scores

44 (b [95% confidence interval (CI)] = 5.37 [2.85, 7.97]) and higher MBI-C total scores (b [95% CI]

45 = 6.09 [2.50, 9.80]). Use of HT did not significantly associate with ECog-II total scores (b [95%

- 46 CI] = -10.98 [-25.33, 6.35]), however, HT was significantly associated with lower MBI-C total
- 47 scores (b [95% CI] = -26.90 [-43.35, -5.67]).
- 48 Conclusions: Menopausal symptom burden is associated with poorer cognitive function and
- 49 more MBI symptoms in mid- to late life. HT may help mitigate symptoms of MBI. These
- 50 findings suggest the experience of menopause may indicate susceptibility to cognitive and
- 51 behavioural changes, both markers of dementia.

52 Introduction

53 As the number of older adults continues to rise, those living with Alzheimer's disease 54 (AD) and related dementias globally are estimated to increase three-fold from 50 million in 2015 55 to 152 million by 2050¹. Females (i.e., assigned female sex at birth) have a three-fold greater risk 56 of developing AD², and will be disproportionately affected by this increasing global dementia 57 burden³. As prevalence of dementia increases with age⁴, the primary explanation offered for the 58 sex discrepancy is greater longevity in females⁵. However, whether longevity alone explains this 59 sex difference remains uncertain; extant literature has proposed there are unique factors that may 60 increase female risk⁴. One proposed factor that may confer special risk to females is the loss of 61 estradiol at menopause.

62 Menopause describes the permanent cessation of menses⁶. There are "many 63 menopauses", each with their own cognitive sequelae⁷, which can occur either spontaneously 64 (i.e., naturally) or due to medical or surgical reasons (e.g., cancer treatments, oophorectomy, 65 hysterectomy) in mid-adulthood⁸. Menopause comprises physiological, cognitive, and 66 behavioural symptoms, likely related to declining 17-b-estradiol (estradiol) levels – the most 67 common type of estrogen⁹. Menopausal symptoms (e.g., poor sleep, depression, etc.) may 68 themselves create risk of later brain pathology, such as the development of AD-related neuropathologies¹⁰⁻¹³. 69

Later-life decline in cognitive function can signal risk of incident dementia^{14,15} and menopause is associated with cognitive changes ^{7,8,16,17}. Recent cross-sectional studies have found spontaneous menopause to be associated with poorer cognitive performance in the domains of language^{18,19}, memory^{8,20-23}, visuo-spatial²⁴, and executive function^{20,24-28}. However, studies have not determined the nature of this association — whether cognition is related to

4

ovarian cessation, itself, or to an additive effect of multiple menopausal symptoms.
Longitudinally, earlier entry into menopause, whether spontaneously or surgically, has been
linked to greater risk of cognitive impairment, AD, and other dementias^{16,17,29-31}. Hormone
therapies (HT) composed of estrogen variations and hormonal contraceptives, including oral
contraceptive, have long been used to ameliorate menopausal symptoms. However, whether HT
use is associated with improvement in cognition or reduced incidence of dementia remains
unclear^{8,32-35}.

82 Analogous to cognitive changes, later-life behavioural changes can also signal risk for 83 incident dementia. The International Society to Advance Alzheimer's Research and Treatment's 84 criteria for the syndrome Mild Behavioral Impairment (MBI)³⁶ operationalizes risk by 85 identifying behavioural and neuropsychiatric symptoms (NPS) that are later-life emergent and 86 persistent. NPS meeting these criteria confer significantly higher risk of incident cognitive 87 decline and dementia compared to conventionally measured behavioural and psychiatric 88 symptomatology³⁷⁻⁴⁷ However, unlike the relationship between ovarian cessation (i.e., any type 89 of menopause) and cognition, evidence is sparse on the association between ovarian cessation 90 and MBI. This evidence gap warrants further investigation.

We investigated the relationship between menopausal symptoms and later-life changes in
cognitive function and behaviour; both risk factors for dementia, which may also represent
preclinical/prodromal AD^{14,15,42,43,48-55}. We hypothesized that individuals who experienced a
greater number of menopausal symptoms (i.e., greater menopausal symptom burden) would
subsequently experience poorer cognitive function and greater MBI symptom burden compared
to individuals who experienced fewer menopausal symptoms.

97 Methods

98 CAN-PROTECT study

99	Data were collected from the ongoing Canadian Platform for Research Online to
100	Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging
101	(CAN-PROTECT) study ⁵⁶ . CAN-PROTECT is a Canada-wide online observational cohort study
102	of brain aging that seeks to assess the roles of demographic, medical, environmental, and
103	lifestyle factors on risk and resilience. To participate in CAN-PROTECT, individuals must be
104	dementia-free residents of Canada, aged ≥ 18 years, with access to an internet-connected
105	computer or tablet. In CAN-PROTECT, participants complete a detailed demographics
106	questionnaire, and an annual series of mandatory and optional online assessments of cognition,
107	behaviour, function, health, wellness, quality of life, medical/psychiatric history, and lifestyle.
108	CAN-PROTECT was approved by the Conjoint Health Research Ethics Board at the University
109	of Calgary and began participant recruitment on March 8, 2024. Informed consent was obtained
110	from all participants at registration.

111 **Participants**

Baseline participant responses pertaining to demographics, cognition, and emotional/psychiatric symptoms were analyzed, in addition to the optional fertility and menopause questionnaire. From the initial sample of 1984 participants (77.7% female), 896 (100% female) who reported being post-menopausal were included here. Of these, 667 had spontaneous menopause, 162 menopause due to hysterectomy/oophorectomy, and 67 menopause due to other medical reasons (Figure 1).

118 Figure 1. Flowchart of participants from CAN-PROTECT included for analysis.

119 Abbreviations: CAN-PROTECT, Canadian Platform for Research Online to Investigate Health,

120 Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging.

121 Measurements

122 Menopausal symptom burden scale

123 The recalled presence or absence of 11 perimenopausal symptoms reflecting vasomotor, 124 cognitive, and behavioural/neuropsychiatric symptoms was assessed using the fertility and 125 menopause questionnaire. The scale comprised 11 symptoms including irregular periods, hot 126 flashes, chills, vaginal dryness, weight gain, slowed metabolism, night sweats, sleep problems, 127 mood symptoms, inattention or forgetfulness, and other unnamed symptoms. Total menopausal 128 symptom burden was calculated by summing the number of self-reported menopausal symptoms 129 experienced by participants. Menopausal symptom burden scores ranged from 0 to 11, with 0 130 representing the least burden (i.e., no symptoms present) and 11 representing the greatest burden 131 (i.e., presence of all 11 symptoms).

132 Everyday cognition scale

133 Cognitive function was measured with the revised Everyday Cognition (ECog-II) Scale⁵⁷, 134 developed to identify new onset cognitive symptoms in dementia at-risk populations. The scale 135 consists of 41 questions that assess changes in memory (9 items), language (8 items), visual-136 spatial and perceptual abilities (8 items), planning (5 items), organization (4 items), and 137 executive function (4 items). Questions are rated from 0-3 (0 = no change, 1 = occasionally138 worse, 2 = consistently a little worse, 3 = much worse) relative to a participant's own baseline, 139 with higher scores reflecting more consistent impairment. Total ECog-II scores were calculated 140 by summing all item scores. Thus, a higher ECog-II total score indicate worse cognitive 141 function.

142 Mild Behavioral Impairment checklist

143	MBI symptoms were assessed using the Mild Behavioral Impairment Checklist (MBI-
144	C) ^{58,59} , developed to identify new onset behavioural symptoms in dementia at-risk populations.
145	The MBI-C consists of 34 items that evaluate later-life emergent and persistent neuropsychiatric
146	symptoms in five domains: apathy (6 items), affect (6 items), impulse dyscontrol (12 items),
147	social cognition (5 items), and psychosis (5 items). Like the ECog-II, MBI-C items are scored
148	from 0-3, with higher scores reflecting greater symptom change from baseline. A total MBI
149	symptom burden score was calculated by summing all item responses to create a total out of 102.
150	Higher MBI-C total scores reflected greater MBI symptom burden.
151	Statistical analysis
152	Participant characteristics were summarized using descriptive statistics (count,
153	percentages, mean, and standard deviation). The data were overdispersed counts (i.e.,
154	variance>mean). Thus, to assess the relationship between menopausal symptom burden and
155	cognitive function, a negative binomial regression model was used. Menopausal symptom
156	burden was treated as the exposure variable and ECog-II total score as the outcome variable.
157	Similarly, to assess the relationship between menopausal symptom burden and MBI
158	symptoms, a zero-inflated negative binomial regression model was used. Menopausal symptom
159	burden was treated as the exposure variable and MBI-C total score as the outcome variable. Both
160	models were adjusted for age, total years of education, type of menopause, age of menopausal
161	onset, and use of HT. Type of menopause consisted of two conditions: 1) spontaneous; and 2)
162	due to surgical or medical reasons. Additionally, the use of HT consisted of three conditions: 1)
163	no HT use; 2) use of progestin or unnamed HT forms; and 3) and use of HT. In both models, two
164	interaction terms were included: 1) age of menopausal onset (participant age of menopausal
165	onset was compared to the mean age of menopausal onset); and 2) use of HT.

166 **Results**

167	Of the 896 included participants assigned female sex at birth, 895 identified as women,
168	while one participant identified as two-spirit. The mean (±standard deviation; SD) age of
169	participants was 64.2±7.3 years with 15.5±5.0 years of education. Participants reported the onset
170	of menopause at a mean age of 49.4±6.5 years; spontaneous menopause, menopause due to
171	hysterectomy/oophorectomy, and menopause due to other medical reasons occurred at the mean
172	ages of 51.3±4.2, 42.0±8.7, and 47.3±5.2 years, respectively. A total of 666 (74.3%) participants
173	experienced menopausal symptoms. To manage perimenopausal symptoms 166 (24.9%)
174	participants used HT, including estradiol-based therapy ($n = 41, 6.2\%$), conjugated estrogens (n
175	= 34, 5.1%), estrogens-progesterone combinations ($n = 73, 11.0\%$), or estrogens-progestin
176	combinations (n = 18, 2.7%). Twelve participants reported the use of progestin (1.8%) and 47
177	reported the use of unnamed HT types (7.1%) (see Table 1 for details of participant

178 demographics).

Demographic Characteristic	n(%)	M(SD)	Range(years - years)
Sex at Birth			
Female	896(100%)		
Male	0(0%)		
Identifies As			
Female	895(99.9%)		
Male	0(0%)		
Two-Spirit	1(0.1%)		

179 **Table 1. Demographic characteristics of participants**

Non-Binary	0(0.0%)		
Other	0(0.0%)		
Age		64.2(7.3)	41-88
Total Years of Education		15.5(5.0)	
Age of Menopausal Onset		49.4(6.5)	12-62
Type of Menopause			
Spontaneous	667(74.4%)	51.3(4.2)	12-62
Hysterectomy and/or	162(18.1%)	42.0(8.7)	12-62
Oophorectomy			
Other Medical Reasons	67(7.5%)	47.5(5.2)	30-58
Experience of Perimenopausal	666(74.3%)		
Symptoms			
HT Use	166(24.9%)		
Estradiol	41(6.2%)		
Conjugated Estrogens	34(5.1%)		
Combination Estrogen-	73(11.0%)		
Progesterone			
Combination Estrogen-	18(2.7%)		
Progestin			
Progestin or Unnamed HT Use			
Progestin	12(1.8%)		
Unnamed HT	47(7.1%)		

Origin

North American	444(49.6%)	
First Nation	17(3.8%)	
Metis	12(2.7%)	
Inuit	0(0.0%)	
European	764(85.3%)	
Caribbean	7(0.8%)	
South American	6(0.7%)	
African	7(0.8%)	
Asian	18(2.0%)	
Oceania	3(0.3%)	

180 Abbreviations: HT, hormone therapies

181 From the list of 11 menopausal symptoms, participants endorsed a range of 0 to 10 (see

Figure 2) and reported a mean menopausal symptom burden of 3.7 ± 2.8 (spontaneous = 3.8 ± 2.8 ,

183 due to surgical or medical reasons = 3.5 ± 2.8). The most frequently endorsed perimenopausal

184 symptom was hot flashes (n = 583, 88%) followed by night sweats (n = 496, 70%). The least

endorsed perimenopausal symptoms were chills (n = 92, 14%) and other symptoms not listed (n

186 = 31, 5%).

187 Figure 2. Reported perimenopausal symptoms.

188 Frequency comparison of participant endorsed and not endorsed perimenopausal symptoms,

189 reported from the CAN-PROTECT fertility and menopause questionnaire. Red bars indicate the

190 number of participants who endorsed a perimenopausal symptom, while grey bars indicate the

191 number of participants who did not.

192 Everyday cognition and Mild Behavioral Impairment

- 193 Collectively, participants reported a mean ECog-II total score of 11.1 ± 10.5 , with a range
- of 0 to 88. Mean MBI-C total symptom burden score was 5.4 ± 7.6 , with a range of 0 to 65.

195 Menopausal symptom burden and cognitive function

- 196 Menopausal symptom burden was associated with poorer cognitive function, according to
- 197 the results of the negative binomial regression model (see Table 2 and Figure 3). Every
- additional menopausal symptom was associated with a 5.37% higher ECog-II total score,
- indicating more consistent symptoms of cognitive dysfunction (95%CI[2.85, 7.97], p<.001).
- 200 Neither the type of menopause (b=2.78%, 95%CI[-13.10, 21.91], p=.75) nor the age of
- 201 menopausal onset (b=-1.05%, 95%CI[-2.13, 0.013], p=.068) was significantly associated with
- 202 ECog-II total score. Similarly, neither HT (b=-10.98%, 95%CI[-25.33, 6.54], p=.20) nor use of
- 203 progestin or unnamed HT (b=16.93%, 95%CI[-10.93, 56.13], p=.27) were significantly
- associated with ECog-II total score.

205 Table 2. ECog-II total score associations

Variable	b%[95% CI]	р
Menopausal Symptom Burden	5.37%[2.85, 7.97]	<0.001*
Type of Menopause	2.78%[-13.10, 21.91]	0.75
Age of Menopausal Onset	-1.05%[-1.17, 0.59]	0.068
Progestin or Unnamed HT Use	16.93%[-10.93, 56.13]	0.27
HT Use	-10.98%[-25.33, 6.53]	0.20
Interaction Variables		
Age of Menopausal Onset	0.26%[-0.26, 0.40]	0.69
Progestin or Unnamed HT Use	2.95%[-8.83, 16.87]	0.43
HT Use	0.50%[-7.30, 9.09%]	0.13

- 206 * Indicates a significant association
- 207 Abbreviations: ECog-II, revised Everyday Cognition Scale; HT, hormone therapies; CI,
- 208 confidence intervals
- 209 Figure 3. ECog-II total score associations.

210 Negative-binomial regression coefficient plot of the relationship between menopausal symptom

211 burden (predictor variable) and ECog-II total score (outcome variable). Lines indicate the 95%

212 confidence intervals for the estimate. Predictor variables whose confidence intervals cross the

- 213 reference line at 1.00 are not significant. Significant predictor variables are indicated with an
- asterisk.

215 None of age of menopausal onset (b=0.070%, 95%CI[-0.26, 0.40], p=.69), use of HT

216 (b=0.50%, 95%CI[-7.30, 9.09], p=.13), or use of progestin or unnamed HT (b=2.95%, 95%CI[-

8.83, 16.87], p=.48) moderated the relationship between menopausal symptom burden and

ECog-II total score.

219 Menopausal symptom burden and Mild Behavioral Impairment

220 Menopausal symptom burden was associated with greater MBI symptom burden, f 221 according to the results of the zero-inflated negative binomial regression (see Table 3 and Figure 222 4). Every additional menopausal symptom was associated with a 6.09% higher MBI-C total 223 score (95%CI[2.50, 9.80], p<.001), indicating more consistent symptoms of MBI. HT use was 224 associated with a 26.90% lower MBI-C total score (95%CI[-43.35, -5.67], p<.016). None of type 225 of menopause (b=4.56%, 95%CI[-18.17, 33.60], p=.72), age of menopausal onset (b=-0.83%, 226 95%CI[-2.36, 0.74], p=.30), or use of progestin or unnamed HT (b=-19.12%, 95%CI[-44.60, 227 18.07], p=.27) were significantly associated with MBI-C total score.

228 Table 3. MBI-C total score associations

Variable	b%[95%CI]	р	
Menopausal Symptom Burden	6.09%[2.50, 9.80]	<0.001*	
Type of Menopause	4.56%[-18.17, 33.60]	0.72	
Age of Menopausal Onset	-0.83%[-2.36, 0.74]	0.30	
Progestin or Unnamed HT Use	-19.12%[-44.60, 18.07]	0.27	
HT Use	-26.90%[-43.35, -5.67]	0.016*	
Interaction Variables			
Age of Menopausal Onset	-0.066%[-0.50, 0.37]	0.77	
Progestin or Unnamed HT Use	7.22%[-8.01, 25.63]	0.37	
HT Use	-0.20%[-11.21, 12.17]	0.97	

229 * Indicates a significant association

230 Abbreviations: MBI-C, Mild Behavioral Impairment Checklist; HT, hormone therapies; CI,

231 confidence intervals

232 Figure 4. MBI-C total symptom score associations.

233 Zero-inflated negative-binomial regression coefficient plot of the relationship between 234 menopausal symptom burden (predictor variable) and MBI-C total score (outcome variable). The 235 count model coefficient estimates are indicated by the conditional title, while the zero-inflated 236 coefficient estimates are indicated by the zero-inflated title. Lines indicate the 95% confidence 237 intervals for the estimate. Predictor variables whose confidence intervals cross the reference line 238 at 1.00 are not significant and indicated by the colour red. Significant predictor variables are 239 indicated by the colour blue. 240 Despite the main effect of HT use and lower MBI-C total score, use of HT did not

241 moderate the relationship between menopausal symptom burden and MBI-C total score (b=-

0.20%, 95%CI[-11.21, 12.17], p=.97). Similarly, neither the age of menopausal onset
(b=0.066%, 95%CI[-0.50, 0.37], p=.77) nor use of progestin or unnamed HT (b= 7.22%,
95%CI[-8.01, 25.63], p=.37) significantly moderated the relationship between menopausal
symptom burden and MBI-C total score.

246 **Discussion**

247 The experience of menopause can include persistent changes in cognitive function and 248 behaviour, which may extend into later life and identify those at greater risk for incident 249 dementia. In this study, we showed that greater menopausal symptom burden was associated 250 with significantly poorer cognitive function and greater MBI symptom burden, adjusted for age, 251 education, age of menopausal onset, type of menopause, use of HT, and use of progestin or 252 unnamed HT. While use of either HT or progestins or unnamed HT was not significantly 253 associated with changes in cognitive function, use of HT was associated with significantly fewer 254 MBI symptoms. Subsequent analyses revealed that age of menopausal onset and use of HT or 255 progestin or unnamed HT did not moderate the observed associations between menopausal 256 symptom burden and cognition or MBI.

257 Changes in cognitive function are a defining feature of the normal aging process in 258 females and males⁶⁰. However, Alzheimer disease starts long before diagnosis and understanding 259 the earliest factors influencing its progression is critical. Therefore, identifying later-life 260 emergent and persistent changes in cognitive function may aid in assessing risk for dementia. 261 Other studies have shown that select perimenopausal symptoms may be associated with 262 cognitive changes. For instance, evidence from cross-sectional studies have found 263 perimenopausal females who experienced specific symptoms were more likely to report poorer 264 cognitive function in the domains of attention^{24,26}, working memory^{8,23}, verbal memory^{18,21,24},

visuo-spatial skills²⁴, and processing speed^{26,27}. However, whether the additive effect of 265 266 experiencing more than one menopausal symptom is related to later-life changes in cognitive 267 function had yet to be determined. Our first analysis suggests that the degree of menopausal 268 symptom burden (i.e., greater number of menopausal symptoms) is indeed associated with 269 poorer mid-to-later life cognitive function. Thus, our findings are novel in that they show not 270 only are specific menopausal symptoms related to changes in cognitive function, but the overall 271 number of menopausal symptoms experienced are important as well. 272 Few studies have investigated the association between multiple perimenopausal 273 symptoms (i.e., menopausal symptom burden) with risk of dementia as determined by both 274 cognitive and behavioural changes. Studies have shown that select perimenopausal symptoms

275 may be related to AD-related neuropathological changes in the brain. For instance,

276 perimenopausal females who experienced night sweats (i.e., a vasomotor symptom) had greater 277 brain amyloid beta pathology than perimenopausal females who did not⁶¹. While such findings 278 suggest that perimenopausal symptoms may be related to risk of dementia, given that participants 279 in our study reported an average of 3.7 perimenopausal symptoms, it is important to recognize 280 that measuring only one symptom does not tell the whole story; symptomatic perimenopausal 281 females may experience more than one symptom at a time. The experience of multiple 282 menopausal symptoms may estimate dementia risk in a way not accounted for by analysis of a 283 single menopausal symptom, as evidenced by the dose effect we found. Further, to identify 284 whether the experience of multiple menopausal symptoms is related to dementia risk, both 285 markers of cognitive change and behavioural change should be used.

286 While changes in cognitive function may act as one marker of dementia risk, later-life 287 emergent and persistent changes in behaviour consistent with MBI are another marker, which

16

288 complements cognition³⁶. Several studies have linked MBI with cognitive decline and dementia. 289 A longitudinal study of MBI in cognitively normal older persons, using sex-stratified analyses, 290 described MBI effects for cognitive decline in both females and males⁶². In a mixed sex study 291 that explored progression to dementia in a neuropsychiatry clinic sample, participants with MBI 292 had a higher progression-rate to dementia than those with psychiatric disorders. Additionally, in 293 both female and male patients with MCI, those with comorbid MBI had a higher progression rate 294 than those without⁶³. These findings have been replicated in a geriatric psychiatry clinic sample⁴⁷ 295 and in observational cohorts of older adults with normal cognition and subjective cognitive decline^{37,64,65}, with MCI^{37,38}, and in mixed cognitively unimpaired/MCI samples^{42,44-46}. These 296 297 findings support MBI as an effect modifier in the relationship between cognitive function and 298 incident dementia. Our cross-sectional study shows that this may also be the case in a cohort of 299 females, alone. This emerging body of evidence highlights the importance of including 300 assessment of behavioural changes, consistent with MBI, in conjunction with the well-301 established practice of determining cognitive status in dementia risk assessment⁶⁶. Despite the 302 importance of the link, sparse research has explored the relationship between menopause and 303 MBI and none exploring dose effects, i.e., number of perimenopausal symptoms and later-life 304 MBI symptoms (let alone cognitive symptoms). Our findings of a dose effect encourage further 305 investigations of this link.

Why some perimenopausal females and not others may experience symptoms has not been elucidated; however, recent evidence suggests that differences in the experience of menopause, such as in menopausal symptoms, may be linked to physiological stressors¹⁰⁻¹³. Estradiol is known to lead to synapse formation, neurite outgrowth, and neurogenesis, all of which decline in neurodegenerative diseases and dementia. However, in menopause, estradiol

17

311 naturally declines^{6,10}. Thus, the experience of menopausal symptoms may act as an indicator of 312 how well females tolerate estradiol changes^{16,67-70}. Indeed, in a 10-year longitudinal study of 313 Vitamin D exposure and incident dementia, the effect of Vitamin D for lower hazard of incident 314 dementia was greater in females, thought to be secondary to the role of estrogen in activating 315 Vitamin D⁶⁷. This evidence suggests two possible mechanisms for how menopause may be 316 related to risk for AD. The first mechanism may be the direct effect of estrogens on neurons^{17,68} 317 with greater decline in estrogens increasing risk for cognitive decline and dementia. The second 318 mechanism may be indirect and dependent on how body systems other than the brain in 319 individual females respond to estrogen decline, modifying risk of developing AD-related 320 neuropathological changes in the brain. Although further exploration is required, it is likely that 321 both mechanisms contribute to the association between estradiol loss, perimenopausal symptoms, 322 and AD.

323 HT are amongst the most effective treatments for alleviating perimenopausal symptoms 324 by mitigating menopause-related estradiol decline^{8,69}. Thus, they are essential to understanding 325 physiological responses to menopause. Given that estrogens have been shown to mitigate against 326 AD cognitive and brain changes ^{16,68,70-73}, some research speculates they may help to reduce to 327 the risk of dementia^{8,16,32,74}. Despite this hypothesis, evidence remains conflicted as studies 328 continue to report mitigating^{8,32,33}, neutral^{34,35}, and harmful^{35,75,76} associations with dementia risk 329 for females. Additionally, factors such as the age at start of therapy, duration, genetic 330 interactions, and type of HT likely complicate the association, making the relationship highly 331 complex and variable person to person^{8,16,33,71,74}.

In our cognitive analysis, we found neither direct nor interaction effects of HT forcognitive function in females independent of menopause type or age at menopause. These

334 findings contradict studies that support the role of HT to ameliorate cognitive decline in females 335 with perimenopausal symptoms ^{8,32,33}. This may be due to the highly variable response of 336 individual females to estradiol loss and replacement and the direction of effect in our study does 337 suggest potential enhancement of cognitive performance. Indeed, our behavioural analysis 338 revealed a main effect for HT and behaviour without an interaction effect, suggesting potential 339 links between HT taken during perimenopause and subsequent behavioural risk for dementia in 340 our cohort. Although research remains sparse, other studies show that the use of HT has been 341 implicated in the improvement of behavioural symptoms during perimenopause, including 342 emotional symptoms^{75,77-80}. One study found that compared to females who experienced no 343 symptoms of menopause, perimenopausal females who used HT had improved depression 344 severity, but only in those who also experienced hot flashes suggesting that the beneficial effects 345 were due to treatment of the hot flashes⁷⁷. Altogether, these findings suggest that HT may 346 mitigate MBI symptoms differently from cognitive symptoms.

347 There are several limitations to this study. First, the cross-sectional design of the study 348 limits conclusions about causality. To determine temporal relationships, longitudinal data are 349 required, ideally with biomarker data (i.e., blood estradiol, phosphorylated-tau, and amyloid beta 350 levels) to further explore potential mechanisms. Second, menopausal symptom burden was 351 operationalized objectively as a symptom count, (i.e., number of menopausal symptoms) rather 352 than severity, which might be more subjective. Nonetheless, recent evidence suggests that 353 menopausal symptom severity is associated with poorer cognitive performance²⁴. Additional 354 research is required to incorporate severity into symptom count, to explore these relationships 355 further. Third, sample size limitations precluded analyses of differences between types and 356 formulations of HT and progestogens. A growing number of studies suggest that 17β-estradiol

357 HT may exert the greatest of neuroprotective effects on cognitive function and risk for AD as 358 compared to other HT estrogens^{81,82}. As we did not find a significant association of HT with 359 cognitive function, it may be that combining different HT estrogens into one group skewed the 360 results. As CAN-PROTECT data accumulate, we may be able to address this limitation in the 361 future. Nonetheless, there are also multiple strengths to this study. The experience of menopause 362 and its association with dementia is highly complex and likely influenced by several variables 363 such as type of menopause, age of onset, and use of HT and progestogens^{8,16,33,71,74}. Our study 364 included each of these variables to represent more accurately the experience of menopause. 365 Finally, contributing to the novelty of our study, we included behaviour, operationalized as the 366 validated construct of MBI to assess risk. Together, changes in cognitive function and behaviour 367 represent two important markers for risk of dementia. Therefore, broadening our understanding 368 of how the experience of menopause may be associated with both cognition and behaviour could 369 have clinical applications for risk for incident dementia.

370 Conclusions

In conclusion, this study has demonstrated that recalled greater menopausal symptom burden is associated with poorer current cognitive function and greater current MBI symptom burden in mid-to-late life. Use of HT control may help to mitigate MBI symptoms more than cognitive symptoms. These findings suggest menopausal symptom burden may predict susceptibility to dementia, as evidenced by greater cognitive and behavioural factors in those with greater menopausal symptom burden.

377 Acknowledgements

378	All authors contributed to the study design, data acquisition, data analysis and interpretation, and
379	manuscript revisions. All authors gave approval for the final submission.
380	REFERENCES
381	
382	1. Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of
383	dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of
384	Disease Study 2019. The Lancet Public Health. 2022;7(2):e105-e125.
385	2. Subramaniapillai S, Almey A, Rajah MN, Einstein G. Sex and gender differences in
386	cognitive and brain reserve: Implications for Alzheimer's disease in women. Frontiers in
387	Neuroendocrinology. 2021;60:100879.
388	3. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and
389	vascular dementia: The EURODEM Studies. Neurology. 1999;53(9):1992-1992.
390	4. Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences
391	between women and men in incidence rates of dementia and Alzheimer's disease. Journal of
392	<i>Alzheimer's disease</i> . 2018;64(4):1077-1083.
393	5. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease:
394	assessing sex and gender differences. Clinical epidemiology. 2014:37-48.
395	6. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs,
396	symptoms, and management options. The Journal of Clinical Endocrinology & Metabolism.
397	2021;106(1):1-15.
398	/. Edwards H, Duchesne A, Au AS, Einstein G. The many menopauses: searching the
399	cognitive research literature for menopause types. <i>Menopause (New York, NY)</i> . 2019;26(1):45.
400	8. Conde DM, Verdade RC, Valadares AL, Mella LF, Pedro AO, Costa-Paiva L.
401	of Druchistry 2021:11(8):412
402	0 Al Azzawi E. Dalacios S. Hormonal abangas during mononousa. Maturitas
403	7. Al-Azzawi F, ratacios S. Hormonal changes during menopause. <i>Maturitas</i> . 2000-63(2):135-137
404	10 Santoro N Ennerson CN Mathews SB Menonausal symptoms and their management
406	Endocrinology and Metabolism Clinics 2015:44(3):497-515
407	11 Lobo RA Davis SR De Villiers T et al Prevention of diseases after menopause
408	<i>Climacteric</i> . 2014:17(5):540-556.
409	12. Faleschini S, Tiemeier H, Rifas-Shiman SL, et al. Longitudinal associations of
410	psychosocial stressors with menopausal symptoms and well-being among women in midlife.
411	Menopause. 2022;29(11):1247-1253.
412	13. Simpson EE. Stress and Coping in the Menopause. <i>Stress: Concepts, cognition, emotion,</i>
413	and behavior. Elsevier; 2016:451-455.
414	14. Farias ST, Mungas D, Reed BR, et al. The measurement of everyday cognition (ECog):
415	scale development and psychometric properties. <i>Neuropsychology</i> . 2008;22(4):531.
416	15. Silverberg NB, Ryan LM, Carrillo MC, et al. Assessment of cognition in early dementia.
417	<i>Alzheimer's & Dementia</i> . 2011;7(3):e60-e76.
418	16. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014
419	update. <i>Molecular and cellular endocrinology</i> . 2014;389(1-2):7-12.

- 420 17. Rocca W, Bower J, Maraganore D, et al. Increased risk of cognitive impairment or
- 421 dementia in women who underwent oophorectomy before menopause. *Neurology*.
- 422 2007;69(11):1074-1083.
- Maki PM, Rubin LH, Savarese A, et al. Stellate ganglion blockade and verbal memory in
 midlife women: evidence from a randomized trial. *Maturitas*. 2016;92:123-129.
- 425 19. Maki P, Thurston R. Menopause and brain health: hormonal changes are only part of the 426 story. Front Neurol. 2020; 11: 562275. 2020.
- 427 20. Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, mood
- 428 and sleep in menopausal transition: the role of menopause hormone therapy. *Medicina*.
 429 2019;55(10):668.
- 430 21. Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE. Objective hot
 431 flashes are negatively related to verbal memory performance in midlife women. *Menopause*432 (*New York, NY*). 2008;15(5):848.
- 433 22. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a
- 434 systematic review and meta-analysis. *The Journal of steroid biochemistry and molecular* 435 *biology*. 2014;142:90-98.
- 436 23. Hampson E. Estrogens, aging, and working memory. *Current psychiatry reports*.
 437 2018;20:1-9.
- 438 24. Kaur M, Kaur M. Is cognitive performance of women sensitive to the severity of 439 menopausal symptoms? *Menopause*. 2022;29(2):170-177.
- 440 25. Fuh J-L, Wang S-J, Lu S-R, Juang K-D, Chiu LM. The Kinmen women-health
- 441 investigation (KIWI): a menopausal study of a population aged 40–54. *Maturitas*.
- 442 2001;39(2):117-124.
- Zhu C, Thomas N, Arunogiri S, Gurvich C. Systematic review and narrative synthesis of
 cognition in perimenopause: The role of risk factors and menopausal symptoms. *Maturitas*.
 2022;164:76-86.
- 446 27. Jaff NG, Rubin LH, Crowther NJ, Norris SA, Maki PM. Menopausal symptoms,
- 447 menopausal stage and cognitive functioning in black urban African women. *Climacteric*.
 448 2020;23(1):38-45.
- 449 28. Huang W, Jiang S, Geng L, Li C, Tao M. Correlation between menopausal symptoms
 450 and everyday cognition in Chinese (peri) menopausal women. *Gynecological Endocrinology*.
 451 2021;37(7):655-659.
- 452 29. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of
 453 premature or early menopause and considerations for management. *Climacteric*. 2015;18(4):483454 491.
- 455 30. Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET. Surgical 456 menopause in association with cognitive function and risk of dementia: a systematic review and 457 meta-analysis. *Psychoneuroendocrinology*. 2019;106:9-19.
- 458 31. Wedatilake Y, Myrstad C, Tom S, Strand B, Bergh S, Selbæk G. Female Reproductive
- Factors and Risk of Mild Cognitive Impairment and Dementia: The HUNT Study. *The Journal* of Prevention of Alzheimer's Disease. 2024:1-10.
- 461 32. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease
- dementia: new findings from the Cache County Study. *Neurology*. 2012;79(18):1846-1852.
- 463 33. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical
- 464 time. Jama. 2002;288(17):2170-2172.

- 465 34. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA.
- 466 Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. *Archives of* 467 *neurology*. 2001;58(3):435-440.
- 468 35. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and 469 Alzheimer disease: A prospective cohort study. *Neurology*. 2017;88(11):1062-1068.
- 470 36. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of
- 471 emergent dementia: provisional diagnostic criteria for mild behavioral impairment. *Alzheimer's*
- 472 & Dementia. 2016;12(2):195-202.
- 473 37. Ismail Z, McGirr A, Gill S, Hu S, Forkert ND, Smith EE. Mild behavioral impairment
 474 and subjective cognitive decline predict cognitive and functional decline. *Journal of Alzheimer's*475 *disease*. 2021;80(1):459-469.
- 476 38. McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia
 477 or reversion to normal cognition in mild cognitive impairment as a function of late-onset
 478 neuropsychiatric symptoms. *Neurology*. 2022;98(21):e2132-e2139.
- 479 39. Rouse HJ, Ismail Z, Andel R, Molinari VA, Schinka JA, Small BJ. Impact of mild
- 480 behavioral impairment on longitudinal changes in cognition. *The Journals of Gerontology:*
- 481 *Series A*. 2024;79(1):glad098.
- 482 40. Kan CN, Cano J, Zhao X, Ismail Z, Chen CL-H, Xu X. Prevalence, Clinical Correlates,
- 483 Cognitive Trajectories, and Dementia Risk Associated With Mild Behavioral Impairment in
 484 Asians. *The Journal of Clinical Psychiatry*. 2022;83(3):40123.
- 485 41. Wolfova K, Creese B, Aarsland D, et al. Gender/sex differences in the association of mild
 486 behavioral impairment with cognitive aging. *Journal of Alzheimer's Disease*. 2022;88(1):345487 355.
- 488 42. Ghahremani M, Wang M, Chen H-Y, et al. Plasma Phosphorylated Tau at Threonine 181
 489 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. *Neurology*.
 490 2023;100(7):e683-e693.
- 491 43. Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detection of
 492 Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral
 493 impairment in ADNI and MEMENTO. *Molecular Neurodegeneration*. 2023;18(1):50.
- 494 44. Ismail Z, Ghahremani M, Amlish Munir M, Fischer CE, Smith EE, Creese B. A
- 495 longitudinal study of late-life psychosis and incident dementia and the potential effects of race496 and cognition. *Nature Mental Health*. 2023;1(4):273-283.
- 497 45. Ebrahim IM, Ghahremani M, Camicioli R, Smith EE, Ismail Z. Effects of race, baseline 498 cognition, and APOE on the association of affective dysregulation with incident dementia: A
- 498 cognition, and APOE on the association of affective dysregulation with incident dementia: A
 499 longitudinal study of dementia-free older adults. *Journal of Affective Disorders*. 2023;332:9-1
- longitudinal study of dementia-free older adults. *Journal of Affective Disorders*. 2023;332:9-18.
 Vellone D, Ghahremani M, Goodarzi Z, Forkert ND, Smith EE, Ismail Z. Apathy and
- 501 APOE in mild behavioral impairment, and risk for incident dementia. *Alzheimer's & Dementia:* 502 *Translational Research & Clinical Interventions*. 2022;8(1):e12370.
- 503 47. Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic. *Journal of Alzheimer's Disease*. 2019;70(2):505-513.
- 505 48. Naude JP, Gill S, Hu S, et al. Plasma neurofilament light: a marker of neurodegeneration 506 in mild behavioral impairment. *Journal of Alzheimer's disease*. 2020;76(3):1017-1027.
- 507 49. Matuskova V, Ismail Z, Nikolai T, et al. Mild behavioral impairment is associated with
- 508 atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. *Frontiers in aging*
- 509 *neuroscience*. 2021;13:643271.

510 50. Ghahremani M, Nathan S, Smith EE, McGirr A, Goodyear B, Ismail Z. Functional 511 connectivity and mild behavioral impairment in dementia-free elderly. Alzheimer's & Dementia: 512 Translational Research & Clinical Interventions. 2023;9(1):e12371. 513 51. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The natural 514 history of cognitive decline in Alzheimer's disease. Psychology and aging. 2012;27(4):1008. 515 Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for estimating the 52. 516 onset of cognitive decline in preclinical Alzheimer's disease. Statistics in medicine. 517 2000;19(11-12):1555-1566. 518 53. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive 519 emergence of the clinical symptoms. Annals of Neurology: Official Journal of the American 520 *Neurological Association and the Child Neurology Society.* 2008;64(5):492-498. 521 Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from 54. 522 healthy aging to Alzheimer disease. Archives of neurology. 2009;66(10):1254-1259. 523 Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory 55. 524 impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. 525 Journal of the International Neuropsychological Society. 2008;14(2):266-278. 526 56. Ismail Z, Guan DX, Vellone D, et al. The Canadian platform for research online to 527 investigate health, quality of life, cognition, behaviour, function, and caregiving in aging (CAN-528 PROTECT): study protocol, platform description, and preliminary analyses. *medRxiv*. 529 2023:2023.12.16.23300094. doi:10.1101/2023.12.16.23300094 530 Farias ST, Weakley A, Harvey D, Chandler J, Huss O, Mungas D. The measurement of 57. 531 Everyday Cognition (ECog): revisions and updates. *Alzheimer disease and associated disorders*. 532 2021;35(3):258. 533 Ismail Z, Agüera-Ortiz L, Brodaty H, et al. The Mild Behavioral Impairment Checklist 58. 534 (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. Journal of 535 Alzheimer's disease. 2017;56(3):929-938. 536 Hu S, Patten S, Charlton A, et al. Validating the Mild Behavioral Impairment Checklist in 59. 537 a Cognitive Clinic: Comparisons With the Neuropsychiatric Inventory Ouestionnaire. J Geriatr 538 Psychiatry Neurol. Mar 2023;36(2):107-120. doi:10.1177/08919887221093353 539 Kester JD, Benjamin AS, Castel AD, Craik FI. Memory in elderly people. Handbook of 60. 540 memory disorders. 2002;2:543-567. 541 Thurston RC, Pauline M, Chang Y, et al. Menopausal Vasomotor Symptoms and Plasma 61. 542 Alzheimer's Disease Biomarkers. American Journal of Obstetrics and Gynecology. 2023; 543 62. Wolfova K, Creese B, Aarsland D, et al. Gender/Sex Differences in the Association of 544 Mild Behavioral Impairment with Cognitive Aging. J Alzheimers Dis. May 16 2022;88(1):345-545 355. doi:10.3233/JAD-220040 546 Taragano FE, Allegri RF, Heisecke SL, et al. Risk of conversion to dementia in a mild 63. 547 behavioral impairment group compared to a psychiatric group and to a mild cognitive 548 impairment group. Journal of Alzheimer's Disease. 2018;62(1):227-238. 549 Mallo SC, Ismail Z, Pereiro AX, et al. Assessing mild behavioral impairment with the 64. 550 mild behavioral impairment checklist in people with subjective cognitive decline. International 551 psychogeriatrics. 2019;31(2):231-239. 552 Creese B, Brooker H, Ismail Z, et al. Mild behavioral impairment as a marker of 65. 553 cognitive decline in cognitively normal older adults. The American Journal of Geriatric 554 Psychiatry. 2019;27(8):823-834.

555 Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus 66. 556 Conference on the diagnosis and treatment of dementia. Alzheimer's & Dementia. 557 2020;16(8):1182-1195. 558 67. Ghahremani M, Smith EE, Chen HY, Creese B, Goodarzi Z, Ismail Z. Vitamin D 559 supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status. 560 Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(1):e12404. 561 Norbury R, Cutter WJ, Compton J, et al. The neuroprotective effects of estrogen on the 68. 562 aging brain. Experimental gerontology. 2003;38(1-2):109-117. 563 69. Kaunitz AM, Manson JE. Management of menopausal symptoms. Obstetrics and 564 gynecology. 2015;126(4):859. 565 70. C Correia S, X Santos R, Cardoso S, et al. Effects of estrogen in the brain: is it a 566 neuroprotective agent in Alzheimer's disease? Current aging science. 2010;3(2):113-126. 567 Pertesi S, Coughlan G, Puthusseryppady V, Morris E, Hornberger M. Menopause, 71. 568 cognition and dementia-A review. Post reproductive health. 2019;25(4):200-206. 569 Rahman A, Schelbaum E, Hoffman K, et al. Sex-driven modifiers of Alzheimer risk: a 72. 570 multimodality brain imaging study. Neurology. 2020;95(2):e166-e178. 571 73. Uddin MS, Rahman MM, Jakaria M, et al. Estrogen signaling in Alzheimer's disease: 572 molecular insights and therapeutic targets for Alzheimer's dementia. Molecular Neurobiology. 573 2020;57:2654-2670. 574 74. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: 575 effects on cognitive function and dementia. Jama. 1998;279(9):688-695. 576 Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition 75. 577 and mood in recently postmenopausal women: findings from the randomized, controlled 578 KEEPS-cognitive and affective study. PLoS medicine. 2015;12(6):e1001833. 579 Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal 76. 580 hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. bmj. 581 2019;364 582 Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms 77. 583 in postmenopausal women after receiving hormone therapy: results from the Heart and 584 Estrogen/Progestin Replacement Study (HERS) trial. Jama. 2002;287(5):591-597. 585 Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal 78. 586 and postmenopausal women: a narrative review. Menopause. 2015;22(5):564-578. 587 79. Kirkham C, Hahn P, VAN VUG D, Carmichael J, Reid R. A randomized, double-blind, 588 placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in 589 hormone replacement therapy. Obstetrics & Gynecology. 1991;78(1):93-97. 590 Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined 80. 591 estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal 592 women. Maturitas. 2003;44(2):157-163. 593 81. Baker LD, Sambamurti K, Craft S, et al. 17β-Estradiol reduces plasma Aβ40 for HRT-594 naive postmenopausal women with Alzheimer disease: a preliminary study. The American 595 journal of geriatric psychiatry. 2003;11(2):239-244. 596 82. Petrovska S, Dejanova B, Jurisic V. Estrogens: mechanisms of neuroprotective effects. 597 Journal of Physiology and Biochemistry. 2012;68:455-460.

598









MBI-C Total Score

Predictors